Florida Senate - 2020 COMMITTEE AMENDMENT
Bill No. SB 1094
Ì4315741Î431574
LEGISLATIVE ACTION
Senate . House
.
.
.
.
.
—————————————————————————————————————————————————————————————————
—————————————————————————————————————————————————————————————————
The Committee on Health Policy (Diaz) recommended the following:
1 Senate Amendment (with title amendment)
2
3 Delete lines 32 - 126
4 and insert:
5 purposes of this subsection, the term “other pharmaceutical
6 services” means the monitoring of the patient’s drug therapy and
7 assisting the patient in the management of his or her drug
8 therapy, and includes reviewing, and making recommendations
9 regarding, review of the patient’s drug therapy and health care
10 status in communication with the patient’s prescribing health
11 care provider as licensed under chapter 458, chapter 459,
12 chapter 461, or chapter 466, or a similar statutory provision in
13 another jurisdiction, or such provider’s agent or such other
14 persons as specifically authorized by the patient, regarding the
15 drug therapy. However, nothing in this subsection may not be
16 interpreted to permit an alteration of a prescriber’s
17 directions, the diagnosis or treatment of any disease, the
18 initiation of any drug therapy, the practice of medicine, or the
19 practice of osteopathic medicine, unless otherwise permitted by
20 law. The term “practice of the profession of pharmacy” also
21 includes any other act, service, operation, research, or
22 transaction incidental to, or forming a part of, any of the
23 foregoing acts, requiring, involving, or employing the science
24 or art of any branch of the pharmaceutical profession, study, or
25 training, and shall expressly permit a pharmacist to transmit
26 information from persons authorized to prescribe medicinal drugs
27 to their patients. The practice of the profession of pharmacy
28 also includes the administration of vaccines to adults pursuant
29 to s. 465.189 and the preparation of prepackaged drug products
30 in facilities holding Class III institutional pharmacy permits.
31 The term also includes ordering and evaluating any laboratory or
32 clinical testing; conducting patient assessments; and modifying,
33 discontinuing, or administering medicinal drugs pursuant to s.
34 465.0125 by a consultant pharmacist.
35 Section 2. Section 465.0125, Florida Statutes, is amended
36 to read:
37 465.0125 Consultant pharmacist license; application,
38 renewal, fees; responsibilities; rules.—
39 (1) The department shall issue or renew a consultant
40 pharmacist license upon receipt of an initial or renewal
41 application that which conforms to the requirements for
42 consultant pharmacist initial licensure or renewal as adopted
43 promulgated by the board by rule and a fee set by the board not
44 to exceed $250. To be licensed as a consultant pharmacist, a
45 pharmacist must complete additional training as required by the
46 board.
47 (a) A consultant pharmacist may provide medication
48 management services in a health care facility within the
49 framework of a written collaborative practice agreement between
50 the pharmacist and a health care facility medical director or a
51 physician licensed under chapter 458 or chapter 459, a podiatric
52 physician licensed under chapter 461, or a dentist licensed
53 under chapter 466 who is authorized to prescribe medicinal
54 drugs. A consultant pharmacist may provide medication management
55 services, conduct patient assessments, and order and evaluate
56 laboratory or clinical testing only for patients of the health
57 care practitioner with whom the consultant pharmacist has a
58 written collaborative practice agreement.
59 (b) A written collaborative practice agreement must outline
60 the circumstances under which the consultant pharmacist may:
61 1. Order and evaluate any laboratory or clinical tests to
62 promote and evaluate patient health and wellness, and monitor
63 drug therapy and treatment outcomes.
64 2. Conduct patient assessments as appropriate to evaluate
65 and monitor drug therapy.
66 3. Modify or discontinue medicinal drugs as outlined in the
67 agreed-upon patient-specific order or preapproved treatment
68 protocol under the direction of a physician. However, a
69 consultant pharmacist may not modify or discontinue medicinal
70 drugs prescribed by a health care practitioner who does not have
71 a written collaborative practice agreement with the consultant
72 pharmacist.
73 4. Administer medicinal drugs.
74 (c) A The consultant pharmacist shall maintain be
75 responsible for maintaining all drug, patient care, and quality
76 assurance records as required by law and, with the collaborating
77 practitioner, shall maintain written collaborative practice
78 agreements that must be available upon request from or upon
79 inspection by the department.
80 (d) This subsection does not authorize a consultant
81 pharmacist to diagnose any disease or condition.
82 (e) For purposes of this subsection, the term “health care
83 facility” means an ambulatory surgical center or hospital
84 licensed under chapter 395, an alcohol or chemical dependency
85 treatment center licensed under chapter 397, an inpatient
86 hospice licensed under part IV of chapter 400, a nursing home
87 licensed under part II of chapter 400, an ambulatory care center
88 as defined in s. 408.07, or a nursing home component under
89 chapter 400 within a continuing care facility licensed under
90 chapter 651 for establishing drug handling procedures for the
91 safe handling and storage of drugs. The consultant pharmacist
92 may also be responsible for ordering and evaluating any
93 laboratory or clinical testing when, in the judgment of the
94 consultant pharmacist, such activity is necessary for the proper
95 performance of the consultant pharmacist’s responsibilities.
96 Such laboratory or clinical testing may be ordered only with
97 regard to patients residing in a nursing home facility, and then
98 only when authorized by the medical director of the nursing home
99 facility. The consultant pharmacist must have completed such
100 additional training and demonstrate such additional
101 qualifications in the practice of institutional pharmacy as
102 shall be required by the board in addition to licensure as a
103 registered pharmacist.
104 (2) Notwithstanding the provisions of subsection (1), a
105
106 ================= T I T L E A M E N D M E N T ================
107 And the title is amended as follows:
108 Delete line 5
109 and insert:
110 465.0125, F.S.; requiring a pharmacist to complete
111 additional training to be licensed as a consultant
112 pharmacist; authorizing a consultant pharmacist to